Literature DB >> 27845686

Lipoprotein lipase activity and interactions studied in human plasma by isothermal titration calorimetry.

Mart Reimund1, Oleg Kovrov1,2, Gunilla Olivecrona2, Aivar Lookene3.   

Abstract

LPL hydrolyzes triglycerides in plasma lipoproteins. Due to the complex regulation mechanism, it has been difficult to mimic the physiological conditions under which LPL acts in vitro. We demonstrate that isothermal titration calorimetry (ITC), using human plasma as substrate, overcomes several limitations of previously used techniques. The high sensitivity of ITC allows continuous recording of the heat released during hydrolysis. Both initial rates and kinetics for complete hydrolysis of plasma lipids can be studied. The heat rate was shown to correspond to the release of fatty acids and was linearly related to the amount of added enzyme, either purified LPL or postheparin plasma. Addition of apoC-III reduced the initial rate of hydrolysis by LPL, but the inhibition became less prominent with time when the lipoproteins were triglyceride poor. Addition of angiopoietin-like protein (ANGPTL)3 or ANGPTL4 caused reduction of the activity of LPL via a two-step mechanism. We conclude that ITC can be used for quantitative measurements of LPL activity and interactions under in vivo-like conditions, for comparisons of the properties of plasma samples from patients and control subjects as substrates for LPL, as well as for testing of drug candidates developed with the aim to affect the LPL system.
Copyright © 2017 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  angiopoietin-like proteins; apolipoproteins; enzymology; lipolysis; triglycerides; very low density lipoprotein

Mesh:

Substances:

Year:  2016        PMID: 27845686      PMCID: PMC5234706          DOI: 10.1194/jlr.D071787

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  60 in total

Review 1.  A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.

Authors:  Anastazia A Kei; Theodosios D Filippatos; Vasilios Tsimihodimos; Moses S Elisaf
Journal:  Metabolism       Date:  2012-02-02       Impact factor: 8.694

2.  ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

Authors:  Philip L S M Gordts; Ryan Nock; Ni-Huiping Son; Bastian Ramms; Irene Lew; Jon C Gonzales; Bryan E Thacker; Debapriya Basu; Richard G Lee; Adam E Mullick; Mark J Graham; Ira J Goldberg; Rosanne M Crooke; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2016-07-11       Impact factor: 14.808

3.  Triacylglycerol-rich lipoproteins protect lipoprotein lipase from inactivation by ANGPTL3 and ANGPTL4.

Authors:  Stefan K Nilsson; Fredrick Anderson; Madelene Ericsson; Mikael Larsson; Elena Makoveichuk; Aivar Lookene; Joerg Heeren; Gunilla Olivecrona
Journal:  Biochim Biophys Acta       Date:  2012-06-21

4.  Characterization of the lipolytic activity of endothelial lipase.

Authors:  Mary G McCoy; Gwo-Shing Sun; Dawn Marchadier; Cyrille Maugeais; Jane M Glick; Daniel J Rader
Journal:  J Lipid Res       Date:  2002-06       Impact factor: 5.922

5.  ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.

Authors:  Viktoria Gusarova; Corey A Alexa; Yan Wang; Ashique Rafique; Jee Hae Kim; David Buckler; Ivory J Mintah; Lisa M Shihanian; Jonathan C Cohen; Helen H Hobbs; Yurong Xin; David M Valenzuela; Andrew J Murphy; George D Yancopoulos; Jesper Gromada
Journal:  J Lipid Res       Date:  2015-05-11       Impact factor: 5.922

Review 6.  Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.

Authors:  Børge G Nordestgaard
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

7.  Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism.

Authors:  Aivar Lookene; Jennifer A Beckstead; Solveig Nilsson; Gunilla Olivecrona; Robert O Ryan
Journal:  J Biol Chem       Date:  2005-05-06       Impact factor: 5.157

8.  Lipoprotein lipase: some effects of activator proteins.

Authors:  G Bengtsson; T Olivecrona
Journal:  Eur J Biochem       Date:  1980-05

9.  The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms.

Authors:  Lu Shan; Xuan-Chuan Yu; Ziye Liu; Yi Hu; Lydia T Sturgis; Maricar L Miranda; Qingyun Liu
Journal:  J Biol Chem       Date:  2008-11-21       Impact factor: 5.157

10.  Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins.

Authors:  P Tornvall; G Olivecrona; F Karpe; A Hamsten; T Olivecrona
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-08       Impact factor: 8.311

View more
  10 in total

Review 1.  An updated ANGPTL3-4-8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues.

Authors:  Ren Zhang; Kezhong Zhang
Journal:  Prog Lipid Res       Date:  2021-11-16       Impact factor: 16.195

2.  On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity.

Authors:  Oleg Kovrov; Kristian Kølby Kristensen; Erika Larsson; Michael Ploug; Gunilla Olivecrona
Journal:  J Lipid Res       Date:  2019-01-27       Impact factor: 5.922

3.  Mapping the sites of the lipoprotein lipase (LPL)-angiopoietin-like protein 4 (ANGPTL4) interaction provides mechanistic insight into LPL inhibition.

Authors:  Aspen R Gutgsell; Swapnil V Ghodge; Albert A Bowers; Saskia B Neher
Journal:  J Biol Chem       Date:  2018-12-27       Impact factor: 5.157

4.  Increased Level of Angiopoietin Like Proteins 4 and 8 in People With Sleep Apnea.

Authors:  Abdulmohsen Al-Terki; Mohamed Abu-Farha; Irina AlKhairi; Preethi T Cherian; Devarajan Sriraman; Ambika Shyamsundar; Shamsha Ali; Fahd Almulla; Jaakko Tuomilehto; Jehad A Abubaker
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-13       Impact factor: 5.555

Review 5.  Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism.

Authors:  Huixing Liu; Daoquan Peng
Journal:  Endocr Connect       Date:  2022-02-07       Impact factor: 3.335

6.  Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma.

Authors:  Oleg Kovrov; Fredrik Landfors; Valeria Saar-Kovrov; Ulf Näslund; Gunilla Olivecrona
Journal:  J Lipid Res       Date:  2021-10-26       Impact factor: 5.922

Review 7.  Novel insights into the pathological development of dyslipidemia in patients with hypothyroidism.

Authors:  Xin Su; Xiang Chen; Hua Peng; Jingjin Song; Bin Wang; Xijie Wu
Journal:  Bosn J Basic Med Sci       Date:  2022-06-01       Impact factor: 3.759

8.  Plasma proteoforms of apolipoproteins C-I and C-II are associated with plasma lipids in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Juraj Koska; Jeremy Furtado; Yueming Hu; Shripad Sinari; Matthew J Budoff; Dean Billheimer; Dobrin Nedelkov; Robyn L McClelland; Peter D Reaven
Journal:  J Lipid Res       Date:  2022-08-09       Impact factor: 6.676

Review 9.  Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8.

Authors:  Kelli L Sylvers-Davie; Brandon S J Davies
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-08-02       Impact factor: 5.900

Review 10.  Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases.

Authors:  Anna Wolska; Mart Reimund; Denis O Sviridov; Marcelo J Amar; Alan T Remaley
Journal:  Cells       Date:  2021-03-08       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.